FDA 483 OBSERVATION · #69 OF 1,945 MOST-CITED

Control procedures to monitor and validate performance

FDA cited this observation 360 times across 330 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs360
BY FISCAL YEAR
FY202616
FY202533
FY202425
FY202331
FY202224
FY202119
FY202018
FY201954
FY201854
FY201748
FY201638

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 211.110

The drug manufacturer did not establish or follow adequate control procedures to monitor the output and validate the performance of the manufacturing processes that may cause variability in the characteristics of in-process material and the finished product.

Why FDA writes it — In-process controls are how you catch variability while a batch can still be corrected. Without them, a process can drift out of control and the problem is only discovered — if at all — at final testing, after the whole batch is affected.

HOW TO COMPLY
  • Establish written procedures to monitor the output and validate the performance of processes that may cause variability in in-process and finished-product characteristics.
  • Define in-process specifications and sampling/testing (e.g., tablet weight, hardness, pH, dissolution as applicable) with valid statistical or scientific bases.
  • Take in-process samples and test at appropriate points, and act when results are out of limits.
  • Reject or investigate in-process material that fails to meet specifications.
WHY FIRMS GET CITED
  • No in-process monitoring, so process drift is only found at final release.
  • In-process limits set without a valid statistical or scientific basis.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 4.9× the rate of the average FDA-cited firm (38.2% vs 7.8%), across 330 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Baxter Healthcare Corporation · Aibonito, Puerto Rico · Drugs · 2026-09-23

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Meridian Medical Technologies, LLC a Subsidiary of Kindeva Drug Delivery, L.P. · Saint Louis, Missouri · Drugs · 2026-06-30

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Hetero Labs Ltd. Unit VI · Mahaboob Nagar · Drugs · 2026-06-26

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Teva Womens Health, LLC · Cincinnati, Ohio · Drugs · 2026-03-20

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Cosmetic Lab, Inc. · Downey, California · Drugs · 2026-03-10

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Gallant Pet Inc · San Diego, California · Drugs · 2026-02-27

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system →Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →